A team of researchers at the University of Southern California has used a commercial blood test to count circulating tumor cells (CTCs) and predict how…
Month: October 2024
A blood test that measures the number of circulating tumor cells (CTCs) at the time of metastatic prostate cancer diagnosis can predict treatment response, disease…
In metastatic hormone-sensitive prostate cancer (mHSPC), new first-line combination therapies have enhanced overall survival (OS), but clinical outcomes for individual patients vary greatly and are…
October 07, 2024 “Prostate cancer is the most common malignancy [among] American men and the second most lethal,” Amir Goldkorn, MD, professor of medicine and biochemistry & molecular…
The non-invasive test, which measures circulating tumor cells in the blood, can predict treatment response, disease progression and overall survival in men newly diagnosed with…